Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    Paper type check (critical)
    The provided text describes a narrative review summarizing phosphorylation–ubiquitination crosstalk in cullin-RING ligases (CRLs) and tumorigenesis; it does not report new experimental results.



     Long Explanation


    BGPT Paper Review (evidence-first, skeptical)
    Phosphorylation regulates cullin-based ubiquitination in tumorigenesis
    DOI: 10.1016/j.apsb.2020.09.007
    Publication context in provided text: Received 27 May 2020; Revised 13 Aug 2020; Accepted 21 Aug 2020
    What this paper actually is (from the provided full-text)
    • This is a qualitative narrative review that compiles mechanistic examples of how phosphorylation can promote or block CRL–substrate (or CRL component) interactions, thereby shifting degradation/stability of oncogenes and tumor suppressors.
    • Because it is a review, claims about efficacy of kinase-targeting strategies are inference based on cited studies and should be treated as hypothesis-generating rather than definitive causal demonstration.
    Quant signals from the provided metadata
    The plot below uses only the BGPT-provided metadata for this paper (e.g., reference count and the review-style scoring fields supplied in the prompt data).
    Mechanistic “logic backbone” (as stated in the review)
    The review’s central mechanistic claim is: phosphorylation mostly affects the last segment of the cullin-based ubiquitination cascade by altering substrate–CRL interaction, with outcomes that can be phosphorylation-site- and context-dependent.
    Note: This figure is presence/absence only (both classes are stated). It is not a claim about how often each occurs across the literature.
    High-value mechanistic checkpoints to scrutinize (skeptical review lens)
    1. Directionality may flip with phosphorylation context. The review repeatedly emphasizes that effects depend on phosphorylation sites and on whether phosphorylation alters recognition positively or negatively.
    2. Phosphorylation can target not only substrates but also CRL components. The review discusses phosphorylation of adaptors/receptors (e.g., SPOP, KEAP1, ZBTB16) altering CRL function and substrate outcomes.
    3. Therapeutic framing is present but remains conditional. The review suggests that kinase inhibitors/activators could modulate phosphorylation→ubiquitination crosstalk to shift protein stability in tumors, including potential combinations (e.g., CDK4/6 inhibitors and anti–PD-1 in the PD-L1/SPOP example).
    Evidence strength vs. knowledge gaps (what would disprove the implied framework)
    Because this is a review, the “disproof” points are about whether the cited mechanistic claims remain robust across contexts.
    • If phosphorylation did not measurably change CRL–substrate or CRL-component interactions (in systems where the review claims it does), then the central mechanism (phosphorylation as a tuning knob for recognition) would be undermined.
    • If kinase modulation produced the reported protein-stability changes but these did not translate into consistent tumor phenotypes, the tumorigenesis link would be at least partially non-causal or context-specific.
    Review bias & reproducibility risks (explicit skepticism)
    • Narrative-review susceptibility. The manuscript synthesizes published studies; narrative selection can overweight well-characterized CRLs/substrates and under-sample contradictory results, and it does not provide standardized quantitative effect sizes across systems.
    • Cross-species transfer risk. The review discusses multiple organisms and pathway contexts; transferability of phosphorylation–CRL rules can be limited by species-specific degron usage, kinase repertoire, and CRL adaptor expression patterns.
    • Mechanistic specificity vs. therapeutic broadness. Kinase inhibitors/activators can have pleiotropic effects on many substrates beyond the phosphorylation→CRL axis, so tumor phenotype changes may reflect combined pathway rewiring rather than the intended crosstalk alone.
    This agent can iteratively build a structured mechanism map (substrate vs adaptor phosphorylation; CRL type; downstream tumor outcome) from the review text you provided.


    Feedback:    

    Updated: March 26, 2026

     BGPT Paper Review


    Study Novelty

    60%

    The review compiles and frames known principles (phosphorylation-controlled degrons, CRL substrate/adaptor recognition, tumorigenesis examples) into a coherent narrative; novelty is largely in synthesis/organization rather than new mechanistic discovery.


    Scientific Quality

    80%

    Good mechanistic coherence and explicit acknowledgment of context dependence and pleiotropy in therapeutic sections; however, as a narrative review, it lacks standardized quantitative synthesis and introduces reproducibility risk typical of narrative literature aggregation.


    Study Generality

    70%

    CRL biology gives broad mechanistic relevance, but the narrative is anchored in selected CRL families/adaptors and cancer exemplars, making generality depend on how completely the review represents the full CRL–phospho landscape.


    Study Usefulness

    70%

    Useful as a mechanistic orientation and hypothesis generator for which kinase-driven phosphorylation steps may alter CRL-mediated degradation/stability in cancers; less directly actionable without the underlying primary datasets and systematic comparisons.


    Study Reproducibility

    40%

    Because it is a narrative review, reproducibility of the paper’s ‘results’ depends on replicating the underlying cited studies; the review itself does not provide original datasets, inclusion criteria, or quantitative aggregation that can be re-run.


    Explanatory Depth

    70%

    Mechanistically interpretable at the pathway level (substrate vs adaptor phosphorylation; recognition vs destabilization/stabilization; tumor suppressor vs oncoprotein examples), but depth is limited by the lack of quantitative, side-by-side dissection across contexts.


    🎁 Authors: Collect 131 Free Science Tokens (≈ $13.1 USD)

    Claim My Author Tokens

    Use for 32 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $13.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Extract kinase/adaptor/substrate/phospho-site tuples from the review text, build an interaction graph, and compute pathway-level summaries (substrate vs adaptor phosphorylation) for prioritizing testable axes.



     Hypothesis Graveyard


    “Phosphorylation always promotes CRL degradation of oncogenes.” This conflicts with the review’s explicit statements that phosphorylation can abrogate CRL recognition and stabilize proteins in some contexts.


    “Kinase inhibition will reliably suppress tumors via the phosphorylation→ubiquitination crosstalk only.” The review notes kinases have other substrates and pleiotropy, so tumor phenotype could be dominated by off-axis effects, making this strong claim unlikely.

     Science Art


    Paper Review: Phosphorylation regulates cullin-based ubiquitination in tumorigenesis Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending